|[April 27, 2012]
FAES FARMA and INVIDA (a MENARINI Company) Announce Agreement to Commercialize Bilastine in 17 Markets in Asia - Pacific
MADRID & SINGAPORE --(Business Wire)--
FAES FARMA, a leading Spanish pharmaceutical group dedicated to
research, development, manufacturing and marketing of pharmaceuticals,
and INVIDA Holdings Private Limited, a Member of the MENARINI Group and
leading specialty biopharmaceutical company focused on the Asia Pacific
region, are pleased to announce the signing of an exclusive long-term
agreement to commercialize bilastine in 17 markets in Asia Pacific.
The agreement allows INVIDA to tap into the strong demand for allergy
products in Asia Pacific and covers the key markets of China and
Australia, along with other important healthcare markets such as
Philippines, Vietnam, Thailand, Singapore, Taiwan and Malaysia. Under
the agreement, FAES will receive upfront and milestone payments and will
be the exclusive supplier of the Active Ingredient to INVIDA for the
Bilastine is a H1 anti-histamine drug
approved for the treatment of allergic
rhinoconjunctivitis and urticaria
in the European Union in 2010 and more recently in some other countries
in Latin America. Based on IMS 4Q2011, the Systemic Antihistamine Market
(R06A) in the Asia Pacific markets was valued at US$ 412 million,
grwing at a 5-year compounded annual growth rate of 13% by value.
INVIDA has a strong track record of commercializing differentiated
pharmaceutical brands across the Asia Pacific markets. INVIDA was
acquired by the MENARINI Group in November 2011, the largest Italian
pharmaceutical company, to expand its presence in the region.
Commenting on the deal, Mr. John Graham, Chief Executive Officer of
INVIDA (Menarini Group) said: "We are honoured that FAES has chosen
INVIDA to spearhead its reach into the Asia Pacific region. The
partnership will enable FAES to leverage on INVIDA's established sales
and marketing force of over 3.500 people, while allowing INVIDA to build
upon FAES's strong reputation and extensive experience. We are confident
that bilastine will be a great addition to our portfolio of high quality
healthcare brands, aiding us in our vision to improve the lives of
people in the Asia Pacific region."
This agreement will reinforce the partnership between FAES and MENARINI,
which already has the rights for bilastine in 51 other countries.
Said Mr. Gonzalo Lopez Casanueva, General Manager of FAES, "With this
licensing agreement, another key milestone has been achieved in FAES'
strategy of licensing bilastine to first class companies and building a
global presence for its H1-antihistamine. INVIDA is our partner of
choice for the Asia Pacific region in this endeavour."
About FAES FARMA
FAES is involved in many phases of the healing process. FAES FARMA
develops, manufactures, and sells prescription pharmaceuticals,
over-the-counter drugs, and chemical raw materials for the
pharmaceutical industry. Cardiovascular, respiratory, and central
nervous system products are key drug categories; FAES also
commercializes therapies for metabolic and inflammatory disorders,
osteoporosis, and other conditions. Most of FAES's sales are in Spain
and Portugal, but sales in the some 60 countries where it operates are
growing, especially in Latin American and African nations. FAES was
founded in 1933.
For more information please visit: http://www.faes.es
About INVIDA HOLDINGS PTE LTD (Menarini Group)
Invida improves the lives of patients in Asia by commercializing
differentiated pharmaceutical and OTC brands - the result of which will
allow all Invida stakeholders to prosper. This is done through proven
brand marketing and sales know-how, strong expertise across a number of
key therapeutic categories and deep experience in all critical Asian
markets. Comprehensive functional capabilities provide rapid market
access delivered by passionate team of professionals.
With over 3,500 employees in 13 markets in Asia Pacific, Invida operates
across the commercial value chain from regulatory approval and product
launch to lifecycle management. We manage a portfolio of proprietary
healthcare brands as well as licensed products from small biotech firms
and large multinational companies. Partnering is a critical component of
Invida's business model. We collaborate closely with our partners in
developing effective strategies and put our extensive experience behind
maximizing the potential of the assets entrusted to us.
For more information please visit: http://www.invida.com
[ Back To TMCnet.com's Homepage ]